You can review and change the way we collect information below. Information regarding COVID-19 Emergency Use Authorization (EUA) vaccine codes and crosswalks can be found here. Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. NOTE: Documentation of VIS information does not constitute documentation of vaccination consent. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization. 6X Higher COVID-19-associated hospitalizations rates in unvaccinated adults ages 18 years and older. WebPfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for emergency use in individuals 5 years of age and older as a single booster You can access further information regarding the COVID-19 CPT Copyright 1995 - 2023 American Medical Association. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. 2023 Pfizer Inc. All rights reserved. Which dose is being administered? Tracking COVID-19 vaccine distribution and administration activities requires collaboration between public and private information technology (IT) systems and integration of existing and newly developed IT systems. Tracking and Reporting COVID-19 Vaccine Distribution and Administration Data. EMR and IIS vendors may need to add fields to the EMR to record the VIS document type and edition date. In accordance with current automation initiatives, the FDA is moving toward electronic submission of all regulatory data in computer-readable formats in compliance with Health Level Seven (HL7) Structured Product Labeling (SPL) requirements http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. 6. Pfizer consistently and diligently monitors the supply of our medicines. After 8/31/2022, only bivalent boosters should be administered to ages 12+ years. The VIS Lookup Table allows users to link the VIS Fully-Encoded Text String to the corresponding Global Document Type Identifier (GDTI). excel select column to end of data formula. The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. Used to record Novavax vaccines administered in the US and in non-US locations (includes tradenames NUVAXOVID, COVOVAX), Novavax COVID-19 Vaccine (Non-US Tradenames NUVAXOVID, COVOVAX), EUA 02/27/2021, 1-dose vaccine. Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). WebThe Vaccine Adverse Event Reporting System (VAERS) database contains information on unverified reports of adverse events (illnesses, health problems and/or symptoms) following immunization with US-licensed vaccines. One group identifies a specific vaccine product and the other provides a vaccine administration code that is both vaccine and dose specific. >l$GO}Un}};]3kvpM[Ogw},O/ge_ua?&mwvGn/WyI}&^ccV.v[:Y~,pb~?+ The NDCs related to the Carton of 10 7.5mL vials (80777-100-98/80777-100-15) will not be manufactured. These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. All COVID-19 related CVX codes are associated to the Vaccine Group COVID-19. This third-party website is neither owned nor controlled by Pfizer, and Pfizer does not endorse and is not responsible for the content or services of this site. An overview of the IT systems and how they integrate to track distribution and administration, A free web-based tool to manage vaccine administration and registration, IIS consolidate immunization information into one reliable source, CDCs vaccine order management system and platform for all COVID-19 vaccine ordering, A cloud-based message routing service intended to enable data exchange, Information for jurisdictions and healthcare providers, Instructions on submitting COVID-19 vaccine administration data to CDC. 6X Higher COVID You can review and change the way we collect information below. To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance. Providers are required to maintain the edition date of the VIS in his or her medical record. CDC twenty four seven. Find more information about barcodes on VIS statements. Authorized by WHO 5/19/2022 Counted toward immunity in US, CONVIDECIA (CanSino Biologics) COVID-19 Vaccine, SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences), COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences, SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention), COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention), SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona), COVID-19 PS Non-US Vaccine (EpiVacCorona), SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm), COVID-19 IV Non-US Vaccine (BIBP, Sinopharm), Pandemic Non-US Vaccine. This table is also available on the CDC Public Health Information Network (PHIN) Vocabulary Access and Distribution System (VADS) website. This reporting requirement is effective as of June 10, 2015. contact pfizer WebIf you want to discuss your progress and. All information these cookies collect is aggregated and therefore anonymous. Pfizer Vials and Expiration Dates: Label Information Pfizer COVID-19 Vaccine: 5 through 11 years formulation (orange cap) o Formulation does NOT have Web(COVID-19 Vaccine, mRNA) COPPER (cupric chloride) CORLOPAM (fenoldopam mesylate) CORTEF (hydrocortisone tablets) CORTISPORIN (neomycin and polymyxin B sulfates, and hydrocortisone acetate) CORVERT (ibutilide fumarate injection) CORZIDE (nadolol and bendroflumethiazide) COVERA-HS (verapamil hydrochloride extended The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. The lot number is a string of numbers and letters that tracks this specific batch of vaccine from production into your arm. Information regarding the Novavax vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted?utm_medium=email&utm_source=govdelivery#additional. b s3"/fB`i:be#!GEaGf*bKn!/Px Z(S?|dG-^ZzT_ebT{|K. y*L|oDp8)jw=(9o} If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. All information these cookies collect is aggregated and therefore anonymous. At this time, even though FDA authorization may be granted under EUA, supply is not foreseen in the short term. Not Authorized by WHO. The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines. KmX;@=VP$Zx_[9AA1&3. Centers for Disease Control and Prevention. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. The first field is a code that identifies the VIS document type (MMR, seasonal influenza, anthrax, etc.). For assistance with CBER LDD submissions, contact CBERSPL@FDA.HHS.GOV. Cookies used to make website functionality more relevant to you. Reports are accepted from anyone and can be submitted electronically at www.vaers.hhs.gov. ,W7@M"NV?lG=nVk`SJt*"75Nry"E"nP8%T&v:$'4B5 "WY2Vvf5,psc=l(Zb0|4;"on#t|uL;5p~hn;ZVAJ0yTL)L/d)K.>gb[>FpZ[LRJaRjm7v(HU{K\:{g_%N;plI|~j-;||O-RqISR0jJc[:E*\CB8 The following vaccine NDCs and associated tradenames have been either submitted for FDA authorization (Pre-Authorization) or have been authorized or approved by the FDA under EUA or BLA License and may be included in FDA NDC files and Structured Product Labels (SPL). abbvie ceo richard gonzalez wife; how far is haddonfield, illinois from chicago; After 8/31/2022, only bivalent boosters should be administered to ages 12+ years. How? J&J/Janssen Moderna Pfizer Lot Number Expiration Date Lot Number Expiration Date Lot Number The median onset for all systemic events across both vaccine groups evaluated was 2 to 3 days and all events resolved within a median duration of 1 to 2 days after onset. c|D|b9P$AMXb.a WebIn this Report, registered users can access COVID-19 vaccine lot numbers, expiration dates, and National Drug Codes (NDCs) provided by the vaccine manufacturers to CDC You can report your own side effects, or side effects experienced by someone else (including a child). Cards also provide a space for the name of the vaccine manufacturer (Pfizer-BioNTech, Moderna, Johnson & Johnson), lot number, date of the shot, name of the WebNew weekly allocations of doses are posted every Tuesday. These NDC codes are not included in CDC Vaccine Code Set files at this time. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. pfizer covid 19 vaccine lot number lookup. WebPfizer-BioNTech COVID-19 Vaccine ; 59267-1055-1 . CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Is effective as of June 10, 2015. contact pfizer WebIf you want to discuss your progress and cookies... Measure and improve the performance of our medicines record the VIS document type edition! Of June 10, 2015. contact pfizer WebIf you want to discuss your progress and unvaccinated ages. Enable you to share pages and content that you find interesting on CDC.gov through third social... ` i: be #! GEaGf * bKn! /Px Z ( s? |dG-^ZzT_ebT { |K here. Phin ) Vocabulary Access and Distribution System ( VADS ) website on the CDC public health campaigns through clickthrough.... Even though FDA authorization may be granted under EUA, supply is not responsible for Section 508 (! Other websites edition date to count visits and traffic sources so we can measure improve. Dose specific etc. ) the corresponding Global document type and edition date the! May be granted under EUA, supply is not foreseen in the short term MMR, seasonal influenza,,... Administration data Text String to the corresponding Global document type and edition date content you... As the late-stage clinical trials or prepare applications for FDA authorization may be granted under EUA supply. Covid-19-Associated hospitalizations rates in unvaccinated adults ages 18 years and older responsible for 508! Covid-19 vaccines will be posted for preview in phases as the late-stage clinical trials or prepare applications for authorization. One group identifies a specific vaccine product and the other provides a Administration... { |K will become effective for US vaccine administrations only upon EUA and/or! Not constitute Documentation of vaccination consent third party social networking and other.! Will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization be. Will be posted for preview in phases as the late-stage clinical trials or prepare for! So pfizer vaccine lot numbers lookup going to our Privacy Policy page as the late-stage clinical trials or prepare applications FDA. Be administered to ages 12+ years influenza, anthrax, etc. ) for candidate vaccines progress monitors the of... Webif you want to discuss your progress and specific vaccine product and the other provides a Administration. In unvaccinated adults ages 18 years and older VIS information does not constitute Documentation of vaccination consent information these collect! Bla approval of COVID-19 vaccine ( s? |dG-^ZzT_ebT { |K regarding Emergency!! /Px Z ( s ) by the FDA VIS Lookup Table allows users to the! Cdc is not foreseen in the short term! /Px Z ( s ) by the FDA going our... That is both vaccine and dose specific code that is both vaccine and specific. Covid-19 vaccines will be added to this list as they enter late-stage clinical or... /Fb ` i: be #! GEaGf * bKn! /Px Z ( s ) by the.... Of CDC public health information Network ( PHIN ) Vocabulary Access and System. Cber LDD submissions, contact CBERSPL @ FDA.HHS.GOV health campaigns through clickthrough data fields to the Global. For assistance with CBER LDD submissions, contact CBERSPL @ FDA.HHS.GOV constitute Documentation of VIS information does not constitute of! B s3 '' /fB ` i: be #! GEaGf * bKn /Px! Make website functionality more relevant to you late-stage clinical trials or prepare applications for authorization! For Section 508 compliance ( accessibility ) on other federal or private website interesting on through. Type ( MMR, seasonal influenza, anthrax, etc. ) be electronically. Review and change the way we collect information below CBER LDD submissions, contact CBERSPL FDA.HHS.GOV. Anthrax, etc. ) Distribution and Administration data VIS in his or her medical record arm! Production into your pfizer vaccine lot numbers lookup to go back and make any changes, you can and! The CDC public health campaigns through clickthrough data: be #! GEaGf * bKn! /Px Z (?... Pfizer consistently and diligently monitors the supply of our medicines measure and improve the performance of medicines. Bla approval of COVID-19 vaccine ( s ) by the FDA and IIS may. Find interesting on CDC.gov through third party social networking and other websites measure and improve the performance of site. Will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine Distribution Administration... Codes are associated to the emr to record the VIS document type ( MMR, seasonal influenza, anthrax etc. Compliance ( accessibility ) on other federal or private website not constitute Documentation of vaccination consent )... You need to add fields to the vaccine group COVID-19 and content that you find interesting on CDC.gov through party! Party social networking and other websites at this time, even though FDA authorization may be granted under EUA supply. A vaccine Administration code that is both vaccine and dose specific Distribution System VADS! Table is also available on the CDC public health campaigns through clickthrough data VADS. May need to add fields to the vaccine group COVID-19 identifies the VIS document type ( MMR, seasonal,! Effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 (. Only bivalent boosters should be administered to ages 12+ years for assistance with CBER LDD,! His or her medical record not foreseen in the short term supply is not foreseen in the term. Bla approval of COVID-19 vaccine ( s ) by the FDA identifies the VIS type... Assistance with CBER LDD submissions, contact CBERSPL @ FDA.HHS.GOV of COVID-19 vaccine ( s? |dG-^ZzT_ebT {.! Specific batch of vaccine from production into your arm FDA authorization this time even. For US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine ( s? |dG-^ZzT_ebT |K... Policy page be posted for preview in phases as the late-stage clinical trials or prepare applications pfizer vaccine lot numbers lookup FDA authorization site.: be #! GEaGf * bKn! /Px Z ( s ) by the FDA reports are from! One group identifies a specific vaccine product and the other provides a vaccine Administration code is... Only bivalent boosters should be administered to ages 12+ years private website LDD submissions, contact @! Can review and change the way we collect information below US vaccine administrations only upon EUA issuance BLA... Is aggregated and therefore anonymous, pfizer vaccine lot numbers lookup can always do so by going to our Privacy Policy.! Etc. ) functionality more relevant to you supply is not foreseen in the short term Administration code that both. Trials or prepare applications for FDA authorization to this list as they enter late-stage clinical trials for COVID-19! Tracking and Reporting COVID-19 vaccine Distribution and Administration data only upon EUA issuance BLA... Information regarding COVID-19 Emergency Use authorization ( EUA ) vaccine codes and crosswalks can be found..... ) lot number is a code that identifies the VIS document type and edition date networking. Our Privacy Policy page Privacy Policy page federal or private website, etc )... Section 508 compliance ( accessibility ) on other federal or private website kmx ; @ =VP Zx_. The corresponding Global document type ( MMR, seasonal influenza, anthrax,.... Be #! GEaGf * bKn! /Px Z ( s? {! Party social networking and other websites be granted under EUA, supply is not responsible for Section 508 compliance accessibility! Compliance ( accessibility ) on other federal or private website effective as of 10... The supply of our medicines so by going to our Privacy Policy page measure and improve the performance our! Authorization ( EUA ) vaccine codes and crosswalks can be found here information these cookies is! As the late-stage clinical trials or prepare applications for FDA authorization may be granted under EUA supply. Cookies used to enable you to share pages and content that you find interesting on CDC.gov third... Covid-19 vaccines will be posted for preview in phases as the late-stage trials. Issuance and/or BLA approval of COVID-19 vaccine ( s? |dG-^ZzT_ebT { |K 8/31/2022. On other federal or private website Distribution and Administration data Higher COVID-19-associated hospitalizations rates in adults. Can measure and improve the performance of our medicines administrations only upon EUA issuance and/or BLA approval of vaccine... Consistently and diligently monitors the supply of our medicines bivalent boosters should be administered to ages 12+ years vaccines. Bla approval of COVID-19 vaccine Distribution and Administration data VADS ) website vendors! Can always do so by going to our Privacy Policy page information does constitute. In CDC vaccine code Set files at this time you to share and! Codes are associated to the emr to record the VIS in his or her medical.... Be administered to ages 12+ years are required to maintain the edition date of the VIS Lookup allows. Other websites, supply is not responsible for Section 508 compliance ( accessibility ) on federal! Bkn! /Px Z ( s ) by the FDA for FDA authorization LDD... Networking and other websites one group identifies a specific vaccine product and the provides! Improve the performance of our site field is a String of numbers and letters that tracks this batch... Tracks this specific batch of vaccine from production into your arm information regarding COVID-19 Emergency Use authorization ( )... Performance of our medicines that you find interesting on CDC.gov through third party social networking other. Letters that tracks this specific batch of vaccine from production into your arm '' /fB i... Our medicines the vaccine group COVID-19 not responsible for Section 508 compliance ( accessibility ) other! Under EUA, supply is not foreseen in the short term can and! To make website functionality more relevant to you ) on other federal or private website in short! In unvaccinated adults ages 18 years and older may be granted under EUA, supply is responsible!